Introduction Adrenal steroidogenesis is essential for human survival and depends on the availability of the precursor cholesterol. Male subjects with low plasma levels of high density lipoprotein (HDL) cholesterol are characterized by decreased adrenal function. Whether this is also the case in female subjects with low plasma HDL-C levels is unresolved to date. Findings 15 female ATP binding cassette transporter AI (ABCAI) and 14 female lecithin-cholesterol acyltransferase (LCAT) were included in the study. HDL-C levels were 38% and 41% lower in ABCA1 and LCAT mutation carriers compared to controls, respectively. Urinary steroid excretion of 17-ketogenic steroids or 17-hydroxy corticosteroids did not differ between 15 female ABCA1 mutation carriers (p = 0.27 vs 0.30 respectively) and 30 matched normolipidemic controls or between 14 female LCAT mutation carriers and 28 matched normolipidemic controls (p = 0.10 and 0.14, respectively). Cosyntropin testing in an unselected subgroup of 8 ABCA1 mutation carriers and 3 LCAT mutation carriers did not reveal differences between carriers and controls. Conclusion Adrenal function in females with molecularly defined low HDL-C levels is not different from controls. The discrepancy with the finding of impaired steroidogenesis in males with molecularly defined low HDL-C levels underscores the importance of gender specific analyses in cholesterol-related research.
References
[1]
Borkowski A, Delcroix C, Levin S (1972) Metabolism of adrenal cholesterol in man. In vivo studies. J Clin Invest 51: 1664–1678.
[2]
Borkowski AJ, Levin S, Delcroix C, Mahler A, Verhas V (1967) Blood cholesterol and hydrocortisone production in man: quantitative aspects of the utilization of circulating cholesterol by the adrenals at rest and under adrenocorticotropin stimulation. J Clin Invest 46: 797–811.
[3]
Hu J, Zhang Z, Shen WJ, Azhar S (2010) Cellular cholesterol delivery, intracellular processing and utilization for biosynthesis of steroid hormones. Nutr Metab (Lond) 7 47 47.
[4]
Illingworth DR, Lees AM, Lees RS (1983) Adrenal cortical function in homozygous familial hypercholesterolemia. Metabolism 32: 1045–1052.
[5]
Illingworth DR, Kenny TA, Orwoll ES (1982) Adrenal function in heterozygous and homozygous hypobetalipoproteinemia. J Clin Endocrinol Metab 54: 27–33.
[6]
Illingworth DR, Kenny TA, Connor WE, Orwoll ES (1982) Corticosteroid production in abetalipoproteinemia: evidence for an impaired response ACTH. J Lab Clin Med 100: 115–126.
[7]
Illingworth DR, Orwoll ES, Connor WE (1980) Impaired cortisol secretion in abetalipoproteinemia. J Clin Endocrinol Metab 50: 977–979.
[8]
Illingworth DR, Alam NA, Lindsey S (1984) Adrenocortical response to adrenocorticotropin in heterozygous familial hypercholesterolemia. J Clin Endocrinol Metab 58: 206–211.
[9]
Yaguchi H, Tsutsumi K, Shimono K, Omura M, Sasano H, et al. (1998) Involvement of high density lipoprotein as substrate cholesterol for steroidogenesis by bovine adrenal fasciculo-reticularis cells. Life Sci 62: 1387–1395.
[10]
Azhar S, Reaven E (2002) Scavenger receptor class BI and selective cholesteryl ester uptake: partners in the regulation of steroidogenesis. Mol Cell Endocrinol 195: 1–26. S0303720702002228 [pii].
[11]
Azhar S, Leers-Sucheta S, Reaven E (2003) Cholesterol uptake in adrenal and gonadal tissues: the SR-BI and ‘selective’ pathway connection. Front Biosci 8: s998–1029.
[12]
Reaven E, Chen YD, Spicher M, Azhar S (1984) Morphological evidence that high density lipoproteins are not internalized by steroid-producing cells during in situ organ perfusion. J Clin Invest 74: 1384–1397 10.1172/JCI111549 [doi].
[13]
Azhar S, Stewart D, Reaven E (1989) Utilization of cholesterol-rich lipoproteins by perfused rat adrenals. J Lipid Res 30: 1799–1810.
[14]
Hoekstra M, Meurs I, Koenders M, Out R, Hildebrand RB et al.. (2008) Absence of HDL cholesteryl ester uptake in mice via SR-BI impairs an adequate adrenal glucocorticoid-mediated stress response to fasting. J Lipid Res 49: 738–745. M700475-JLR200 [pii]; 10.1194/jlr.M700475-JLR200 [doi].
[15]
Hoekstra M, Ye D, Hildebrand RB, Zhao Y, Lammers B, et al. (2009) Scavenger receptor class B type I-mediated uptake of serum cholesterol is essential for optimal adrenal glucocorticoid production. J Lipid Res 50: 1039–1046.
[16]
van der Voort PH, Gerritsen RT, Bakker AJ, Boerma EC, Kuiper MA, et al. (2003) HDL-cholesterol level and cortisol response to synacthen in critically ill patients. Intensive Care Med 29: 2199–2203.
[17]
Marik PE, Gayowski T, Starzl TE (2005) The hepatoadrenal syndrome: a common yet unrecognized clinical condition. Crit Care Med 33: 1254–1259.
[18]
Vergeer M, Korporaal SJ, Franssen R, Meurs I, Out R, et al. (2011) Genetic variant of the scavenger receptor BI in humans. N Engl J Med 364: 136–145.
[19]
Bochem AE, Holleboom AG, Romijn JA, Hoekstra M, Dallinga GM et al.. (2013) High-density lipoprotein as a source of cholesterol for adrenal steroidogenesis; a study in individuals with low plasma HDL-C. J Lipid Res. jlr.P033449 [pii]; 10.1194/jlr.P033449 [doi].
[20]
Duivenvoorden R, Holleboom AG, van den Bogaard B, Nederveen AJ, de Groot E et al.. (2011) Cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging carriers of lecithin. J Am Coll Cardiol 58: 2481–2487. S0735-1097(11)03425-5 [pii]; 10.1016/j.jacc.2010.11.092 [doi].
[21]
Candini C, Schimmel AW, Peter J, Bochem AE, Holleboom AG, et al. (2010) Identification and characterization of novel loss of function mutations in ATP-binding cassette transporter A1 in patients with low plasma high-density lipoprotein cholesterol. Atherosclerosis 213: 492–498.
[22]
van Dam MJ, de Groot E, Clee SM, Hovingh GK, Roelants R, et al. (2002) Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet 359: 37–42.
[23]
Holleboom AG, Kuivenhoven JA, Peelman F, Schimmel AW, Peter J et al.. (2011) High prevalence of mutations in LCAT in patients with low high-density lipoprotein cholesterol levels in the netherlands identification and characterization of 8 new mutations in lcat. Hum Mutat 10.
[24]
van de Calseyde JF, Scholtis RJ, Schmidt NA, Leijten CJ (1972) Profiling urinary steroids. A reliable procedure. Clin Chim Acta 38: 103–111.
[25]
Weykamp CW, Penders TJ, Schmidt NA, Borburgh AJ, van de Calseyde JF, et al. (1989) Steroid profile for urine: reference values. Clin Chem 35: 2281–2284.
[26]
Coolens JL, Van Baelen H, Heyns W (1987) Clinical use of unbound plasma cortisol as calculated from total cortisol and corticosteroid-binding globulin. J Steroid Biochem 26: 197–202.
[27]
Doi SA, Lasheen I, Al-Humood K, Al-Shoumer KA (2006) Relationship between cortisol increment and basal cortisol: implications for the low-dose short adrenocorticotropic hormone stimulation test. Clin Chem 52: 746–749. clinchem.2005.061267 [pii]; 10.1373/clinchem.2005.061267 [doi].
[28]
Thaler LM, Blevins LS Jr (1998) The low dose (1-microg) adrenocorticotropin stimulation test in the evaluation of patients with suspected central adrenal insufficiency. J Clin Endocrinol Metab 83: 2726–2729.
[29]
Smith SC Jr, Allen J, Blair SN, Bonow RO, Brass LM et al.. (2006) AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute. Circulation 113: 2363–2372. 113/19/2363 [pii]; 10.1161/CIRCULATIONAHA.106.174516 [doi].
[30]
Fraser R, Ingram MC, Anderson NH, Morrison C, Davies E, et al. (1999) Cortisol effects on body mass, blood pressure, and cholesterol in the general population. Hypertension 33: 1364–1368.
[31]
Holleboom AG, Kuivenhoven JA, Vergeer M, Hovingh GK, van Miert JN et al.. (2010) Plasma levels of lecithin:cholesterol acyltransferase and risk of future coronary artery disease in apparently healthy men and women: a prospective case-control analysis nested in the EPIC-Norfolk population study. J Lipid Res 51: 416–421. P900038-JLR200 [pii]; 10.1194/P900038-JLR200 [doi].
[32]
Clark PM, Neylon I, Raggatt PR, Sheppard MC, Stewart PM (1998) Defining the normal cortisol response to the short Synacthen test: implications for the investigation of hypothalamic-pituitary disorders. Clin Endocrinol (Oxf) 49: 287–292.
[33]
Puder JJ, Freda PU, Goland RS, Wardlaw SL (2001) Estrogen modulates the hypothalamic-pituitary-adrenal and inflammatory cytokine responses to endotoxin in women. J Clin Endocrinol Metab 86: 2403–2408.
[34]
Papadopoulos AD, Wardlaw SL (2000) Testosterone suppresses the response of the hypothalamic-pituitary-adrenal axis to interleukin-6. Neuroimmunomodulation 8: 39–44. 26451 [pii]; 26451 [doi].
[35]
Bethin KE, Vogt SK, Muglia LJ (2000) Interleukin-6 is an essential, corticotropin-releasing hormone-independent stimulator of the adrenal axis during immune system activation. Proc Natl Acad Sci U S A 97: 9317–9322. 97/16/9317 [pii].
[36]
Path G, Bornstein SR, Ehrhart-Bornstein M, Scherbaum WA (1997) Interleukin-6 and the interleukin-6 receptor in the human adrenal gland: expression and effects on steroidogenesis. J Clin Endocrinol Metab 82: 2343–2349.
[37]
O’Connor MF, Motivala SJ, Valladares EM, Olmstead R, Irwin MR (2007) Sex differences in monocyte expression of IL-6: role of autonomic mechanisms. Am J Physiol Regul Integr Comp Physiol 293: R145–R151. 00752.2006 [pii]; 10.1152/ajpregu.00752.2006 [doi].
[38]
Silva C, Ines LS, Nour D, Straub RH, da Silva JA (2002) Differential male and female adrenal cortical steroid hormone and cortisol responses to interleukin-6 in humans. Ann N Y Acad Sci 966: 68–72.
[39]
Calabresi L, Baldassarre D, Castelnuovo S, Conca P, Bocchi L et al.. (2009) Functional lecithin: cholesterol acyltransferase is not required for efficient atheroprotection in humans. Circulation 120: 628–635. 120/7/628 [pii]; 10.1161/CIRCULATIONAHA.108.818143 [doi].
